Trial Profile

Clinical Study Evaluating the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 01 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CDH17/GUCY2C CAR-T cell therapy Guangzhou Bio-gene Technology (Primary) ; CDH17/GUCY2C CAR-T cell therapy Guangzhou Bio-gene Technology (Primary)
Indications Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Guangzhou Bio-gene Technology

Most Recent Events

28 May 2026 Status changed from recruiting to withdrawn prior to enrolment.Reason the study was stopped: Due to corporate strategic adjustment.
12 Sep 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com